Engineered phage-derived lysins effectively kill mycobacterial pathogens

Treatment of mycobacterial infections is difficult due to poor penetration of antibiotics across the complex cell envelope. We engineered phage-inspired lytic proteins, mycolysins, that selectively breach this barrier and enable rapid bacterial clearance in pulmonary and wound infection models, highlighting a programmable biologic platform to enhance and shorten existing therapies.